Mepolizumab is approved for treating severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES) [1]. The drug targets the interleukin-5 (IL-5) pathway, which plays a crucial role in eosinophilic inflammation [1][2].
What is Mepolizumab's mechanism of action?
Mepolizumab is a monoclonal antibody that binds to IL-5 [1]. By inhibiting IL-5, it reduces the production, maturation, recruitment, and survival of eosinophils [1][3]. This reduction in eosinophils is key to managing conditions characterized by excessive eosinophil counts.
How is Mepolizumab administered?
Mepolizumab is administered as a subcutaneous injection [1]. The dosage and frequency depend on the specific condition being treated. For severe eosinophilic asthma and EGPA, it is typically given every four weeks after an initial loading dose [1]. For HES, it is also administered every four weeks [1].
What are the approved indications for Mepolizumab?
Mepolizumab, marketed as Nucala, is approved for the following indications:
* Severe Eosinophilic Asthma: For patients aged six and older whose asthma is not adequately controlled with inhaled corticosteroids and other maintenance treatments [1].
* Eosinophilic Granulomatosis with Polyangiitis (EGPA): For adult patients with EGPA whose disease is relapsing or refractory [1].
* Hypereosinophilic Syndrome (HES): For adult patients with HES who have a $>1500$ eosinophils/µL in blood who are not considered eligible for treatment with chronic oral corticosteroids [1].
* Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): For adult patients with CRSwNP whose disease is not adequately controlled with nasal corticosteroids [1].
What are the potential side effects of Mepolizumab?
Common side effects reported with mepolizumab include headache and injection site reactions [1]. Rare but serious reactions like herpes zoster have also been observed [1]. Patients should report any new or worsening symptoms to their healthcare provider [1].
When does Mepolizumab's patent exclusivity expire?
Patent expiry dates for drugs like mepolizumab can be complex and involve multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use [4]. Information on specific patent expiry timelines and potential challenges can be found on resources like DrugPatentWatch.com [4].
Can biosimilar versions of Mepolizumab be developed?
The development of biosimilar versions of monoclonal antibodies like mepolizumab is possible, but it is a lengthy and complex process. Biosimilars must demonstrate high similarity to the reference product in terms of structure, function, and clinical performance, without clinically meaningful differences [5]. Regulatory pathways exist for approving biosimilar products once patent exclusivity has expired or is no longer a barrier.